| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
BridgeBio Oncology Therapeutics, Inc.
13G
BBOT · 107924102
|
5.5% |
9/3/2025
Event 9/4/2025
|
||||
| BC Global Opportunities IX LP | 5.5% | |||||
| BC General Partner, LP | 5.5% | |||||
| BC Capital Management Limited | 5.5% | |||||
| Tan Kuangming | 5.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.